Our data showed that the p-ULK1/ULK1 protein levels increased as early as 3 h after GSK-3β inhibitor (AR-A014418) treatment in the high and intermediate grade BC cells and decreased with time, whereas no such trend was observed in the low grade BC cells or normal kidney cells. Here, GSK3B is linked to breast cancer.